Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells

• 来源期刊: 细胞研究（英文版）
• 年，卷（期）: 2014,（9）
• 页码范围: 1141-1145
• 页数: 5页
• 语种: 中文
• DOI: 10.1038/cr.2014.86

摘要

Dear Editor, Because multiple cancers require Polo-like kinase (Plk) 1 for survival [1-3],Plk1 has been investigated intensively as a target for novel anti-cancer agents [4-6].Although many small molecule Plk1 inhibitors have reached the clinic,our knowledge about their target profiles is limited,because their biochemical properties are determined mostly using in vitro kinase assays.It remains unclear whether this approach reflects the true pharmacodynamic properties of Plk1 inhibitors,since these assays often address only small portions of the human kinome and typically use a recombinant kinase and an artificial substrate.